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immune symptoms in a patient car-
rying a de novo variant in CTLA-4To the Editor:
Inhibitory immune receptors presented on regulatory T (Treg)
cells provide a critical balance in immune modulation by
interacting with ligands expressed in antigen-presenting cells.
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) on Treg cells
suppresses immune reactions by interacting with CD80 and
CD86, which are displayed by antigen-presenting cells, making
it a useful target for immune modulation. Haploinsufficiency of
CTLA-4 in human or knockout of the gene in mouse leads to im-
mune dysregulation.1-3 Here we describe a patient who presented
with severe multiorgan autoimmune disorders. Genetic analysis
of the patient genome revealed a functional mutation in CTLA-
4, and treatment with CTLA-4-Ig agent, a CTLA-4 mimetic, re-
constructed Treg-cell functionality and improved the patient’s
condition, suggesting CTLA-4-Ig agent as a potential therapeutic
solution for autoimmune patients with CTLA-4 mutation.
The patient is a 14-year-old Korean girl who has suffered from
chronic diarrhea since age 3 months (Fig 1, A, and see Fig E1 in
this article’s Online Repository at www.jacionline.org). At the
age of 4 years, esophagogastroduodenoscopy with biopsy re-
vealed villi atrophy and heavy lymphoplasma cell infiltration in
the lamina propria of the duodenum, leading to the diagnosis of
autoimmune enteropathy (see Fig E2 in this article’s Online Re-
pository at www.jacionline.org). At the age of 7 years, she devel-
oped anemia with vitamin B12 deficiency. Autoimmune hepatitis
was diagnosed at the age of 8 yearswith periodically high levels of
AST (aspartate transaminase, >1000 IU/L) and ALT (alanine
transaminase, >1000 IU/L) and liver biopsy. Antiplatelet 2015 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma& Immunology. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).antibody and smooth muscle antibody signal turned positive,
and transiently elevated IgG level was noted (see Table E1 in
this article’s Online Repository at www.jacionline.org). At the
age of 11 years, the patient was admitted with high fever (398C)
and jaundice accompanied by pancytopenia. Direct Coombs test
result was positive. Bone marrow examination for the evaluation
of pancytopenia revealed hemophagocytosis, and corticosteroids
and antibiotics were applied. Subsequently, pulmonary aspergil-
losis and sepsis were observed. At age 12 years, she developed
hematochezia and endoscopic evaluation revealed mixed tubular
adenocarcinoma of the stomach (stage 1, T3, N0; see Fig E3 in
this article’s Online Repository at www.jacionline.org). She un-
derwent a subtotal gastrectomy with surgical liver wedge biopsy.
Hepatic pathology showed micronodular liver cirrhosis. Multiple
areas of joint pain were noted before the surgery. She remained
below the third percentile of Korean growth references for height
and weight and virtually stopped growing after the surgery (see
Fig E4 in this article’s Online Repository at www.jacionline.
org). Multiple rounds of immunosuppressants were administrated
during the course, but none achieved substantial improvements
(see Fig E1). The patient does not carry any notable protein-
altering variants in FOXP3 or AIRE by Sanger sequencing,
excluding the possibility of suffering from these genetically pre-
defined autoimmune syndromes.
Whole-exome sequencing of the patient and her healthy
parents led to the discovery of a nonsynonymous de novo variant
(p.Pro138Thr) inCTLA-4 (Fig 1,B; see Tables E2, E3, and E5 and
Figs E5-E8 in this article’s Online Repository at www.jacionline.
org). The point mutation lies in the extracellularMYPPPY ligand-
binding motif (Fig 1, C).4 The motif is well conserved in most of
the vertebrates, and the mutated residue Pro138 is completely
conserved in all the vertebrate species examined. Structural
analysis demonstrated that the motif forms the ligand interacting
surface for CD80 and CD86 (Fig 1, D; see Fig E9 in this article’s
Online Repository at www.jacionline.org).5,6 Reconstructing
T-cell stimulation in vitro demonstrated that the expression of
wild-type CTLA-4 in Jurkat cells successfully implemented the
immune modulation activity as assayed by IL-2 production while
the introduction of the mutation into CTLA-4 eliminated the im-
mune modulation activity (Fig 1, E).
Next, we tested whether controlling the CTLA-4–mediated
signal through medication could improve the patient’s condition.
Abatacept (Orencia) is a fusion protein formed by an IgG1 Fc
region linked with the extracellular domain of CTLA-4 (CTLA-
4-Ig), and is commonly used to alleviate rheumatoid arthritis
symptoms. Notably, there was a recent case report on abatacept
treatment in an adult with idiopathic autoimmune enteropathy.7
To investigate the molecular effect of the drug, we sampled the
patient’s blood at the trough level (ie, 0 day) and at 1, 4, 6, and
8 days (among these, samples from the trough level and days 4
and 8 were subjected to the fluorescence-activated cell sorting
analysis) after the administration of the drug (Fig 2, A-D; for
drug treatment details, see the Methods section in this article’s
Online Repository at www.jacionline.org). Notably, the propor-
tion of CD251 Treg cells (CD41CD251FOXP31 or
CD41CD25highCD1272 cells) was lower in the patient than in
healthy donors while the proportion of CD41FOXP31 cells was
not reduced in the patient when compared with healthy donors,
as appeared in the previous report on patients with CTLA-4 hap-
loinsufficiency (Fig 2, A; see Fig E10 in this article’s Online Re-
pository at www.jacionline.org).1Moreover, administration of the
FIG 1. De novo CTLA-4 mutation in early-onset multiorgan autoimmune disease. A and B, Disease course
and pedigree of the patient. C, The evolutionary conservation of the mutated reside. D, Structure of CTLA-4
homodimer (right)5 and interaction with CD80 (left).6 E, Overexpressed CTLA4P138T lost the ability to sup-
press IL-2 production in Jurkat cells. A.m., Alligator mississippiensis; B.t., Bos taurus; D.r., Danio rerio;
G.g., Gallus gallus; H.s., Homo sapiens; M.m., Mus musculus; O.c., Oryctolagus cuniculus; X.l., Xenopus
laevis. **P < .005.
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expression as indicated by the proportion of CD41FOXP31 cells
(Fig 2, A; see Fig E11 in this article’s Online Repository at www.
jacionline.org). This suggests a restoration of Treg-cell function,
possibly through the wild-type allele of CTLA-4, as FOXP3 is a
Treg-cell function regulator.8 Unlike the previous reports with
patients having haploinsufficiency of CTLA-4 expression, our pa-
tient showed even higher CTLA-4 expression in Treg cells
(CD41CD251FOXP31) than did healthy donors (Fig 2, B).1,2
Remarkably, the drug treatment effectively reduced CTLA-4
expression in Treg cells, as demonstrated by fluorescence-
activated cell sorting and quantitative RT-PCR analyses (Fig 2,
B and C), indicating a reduced proliferation of Treg cells as a
proliferating Treg-cell preferentially expresses CTLA-4.9 The
drug treatment increased TGF-b1 expression level, demon-
strating that the drug successfully restores Treg-cell functionality
(Fig 2, C; see Table E5).10 The drug treatment restored CD31
T-cell level and attenuated inflammatory cytokine production
such as IL-10, IL-17A, and IL-6 from patient-derived PBMCs
(Fig 2, D; see Table E4 in this article’s Online Repository at
www.jacionline.org). Initial serum levels of IL-10, IL-17A, and
IL-6 were higher in the patient than in her healthy parents, and
the increased serum cytokine levels were reduced in a similar
fashion by the drug treatment (see Fig E12 in this article’s Online
Repository at www.jacionline.org).
Clinically, treatment with abatacept without other immuno-
suppressants reduced diarrhea output by about 67% (from 3 L/d to
1 L/d) and her stool consistency has recently improved from
watery to partially formed status. Remarkably, the blood trans-
fusion volume has dropped to zero (Fig 2, E and F), allowing the
patient to be free of the other immunosuppressants. She wasdischarged to outpatient carewith partial parenteral nutrition after
3 years of hospitalization. Her direct Coombs test results turned
negative after 8 months of abatacept treatment. After cessation
of the steroid, hyperglycemia and adrenal insufficiency were
easily controlled.
Here we report a direct effect of CTLA-4 dysfunction in
human; enhancing the CTLA-4–mediated signal with CTLA-4-Ig
toned down immune responses in a patient with severe autoim-
mune features, eventually achieving substantial clinical improve-
ments. Therefore, it would be worthwhile to investigate patients
with idiopathic autoimmune features for additional CTLA-4
mutations that may affect proper protein function and use
CTLA-4-Ig as a potential therapeutic solution.
We appreciate participation of the patient and her family in this study. We
are grateful to J.-A. Kim and C. R. Hong for their assistance in collecting
patient information, H.-R. Kim for reagents, J. Y. Park for flow cytometry
assistance, Y. Yoo for technical assistance, and U. Scholl and S. Shibata for
comments on the manuscript.
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FIG 2. CTLA-4-Ig agent abatacept controls immune reactivity of the patient. A, Treg-cell
(CD41CD251FOXP31) population in healthy donors (HD) and the patient. B, CTLA-4 expression level in
CD41CD251FOXP31 cells. C, Quantitative RT-PCR of Treg-cell markers from the patient-isolated Treg cells.
D, Concentration of cytokines from patient-derived PBMC culture supernatant. E and F, Patient blood levels
of hemoglobin and platelet (gray and smoothened black lines) plotted against RBC and platelet transfusion
rates (gray bars). Period and actual administration of abatacept treatment are depicted as a black line with
dots. MFI, Mean fluorescence intensity. *P < .05 and **P < .005.
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